{"url_path":"/sec/ptpi/8-k/2026-06-05/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-071027-index.html","accession_number":"0001104659-26-071027","cik":"0001815903","ticker":"PTPI","issuer_name":"Petros Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-071027-index.html","primary_entity_key":"0001815903","primary_entity_name":"Petros Pharmaceuticals, Inc."},"word_count":306,"has_tables":true,"body_markdown":"false\n0001815903\n\n0001815903\n\n2026-06-05\n2026-06-05\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 OR 15(d) of the Securities\nExchange Act of 1934\n\n \n\nDate of Report (Date of earliest event reported):\n**June 5, 2026**\n\n \n\n**Petros\nPharmaceuticals, Inc.**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n**Delaware**\n\n(State or other\n\njurisdiction of\n\nincorporation)\n\n**001-39752**\n\n(Commission\n\nFile Number)\n\n**85-1410058**\n\n(I.R.S. Employer\n\nIdentification No.)\n\n** **\n\n**1185 Avenue of the Americas, 3rd Floor**\n\n**New York, New York 10036**(Address of principal executive offices) (Zip code)\n\n** **\n\n**(973) 242-0005**(Registrant's telephone number, including area code)\n\n \n\n**Not applicable**\n\n(Former name or former address, if changed\nsince last report)\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any\nof the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)\n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act: None\n\n \n\n**Title of each class**\n**Trading Symbol(s)**\n**Name of each exchange on\nwhich registered**\n\nNone\nNone\nNone\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company x\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}